Development of a hydrogen peroxide-inactivated vaccine that protects against viscerotropic yellow fever in a non-human primate model.
Cell Rep Med
; 5(7): 101655, 2024 Jul 16.
Article
en En
| MEDLINE
| ID: mdl-39019010
ABSTRACT
Yellow fever virus (YFV) is endemic in >40 countries and causes viscerotropic disease with up to 20%-60% mortality. Successful live-attenuated yellow fever (YF) vaccines were developed in the mid-1930s, but their use is restricted or formally contraindicated in vulnerable populations including infants, the elderly, and people with compromised immune systems. In these studies, we describe the development of a next-generation hydrogen peroxide-inactivated YF vaccine and determine immune correlates of protection based on log neutralizing index (LNI) and neutralizing titer-50% (NT50) studies. In addition, we compare neutralizing antibody responses and protective efficacy of hydrogen peroxide-inactivated YF vaccine candidates to live-attenuated YFV-17D (YF-VAX) in a rhesus macaque model of viscerotropic YF. Our results indicate that an optimized, inactivated YF vaccine elicits protective antibody responses that prevent viral dissemination and lethal infection in rhesus macaques and may be a suitable alternative for vaccinating vulnerable populations who are not eligible to receive replicating live-attenuated YF vaccines.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Fiebre Amarilla
/
Virus de la Fiebre Amarilla
/
Vacunas de Productos Inactivados
/
Vacuna contra la Fiebre Amarilla
/
Modelos Animales de Enfermedad
/
Anticuerpos Neutralizantes
/
Peróxido de Hidrógeno
/
Macaca mulatta
/
Anticuerpos Antivirales
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Cell Rep Med
Año:
2024
Tipo del documento:
Article
País de afiliación:
Estados Unidos